The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
News|Articles|September 28, 2026
Alopecia Areata Awareness Month: 2026 in Review
Author(s)Shannon Heaning, Content Associate
From emerging therapies to earlier intervention and psychosocial support, Dermatology Times looks back at key alopecia areata developments in 2026.
Advertisement
Advertisement
September marks
Related to this article
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
This review of the latest dermatological studies includes insights on artificial intelligence, interstitial granulomatous dermatitis and atopic dermatitis
Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
This review of the latest dermatological studies includes insights on stem cell therapies for skin rejuvenation, smoke exposure in HS, hair loss in pediatric IBD, and more.
An HS toolbox with wound care, symptom relief, and personal care supplies can help patients stay prepared for unexpected flares.
Advertisement
Advertisement